NBP Healthcare

NovaBridge Biosciences

$1.01-5.61%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 116.8M USD
Enterprise value: -28.1M USD
Full-time employees: 30

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.50 vs a peer median of 0.63)bigger price swings (beta 1.50 vs peers 0.63)
Not enough data: growth

Would rank #825 of 1,157 fully scored healthcare companies (bottom 29%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 39% from December 2022 to December 2025.
NovaBridge Biosciences had 39% more shares at December 2025 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.NovaBridge Biosciences had 39% more shares at December 2025 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.
NovaBridge Biosciences's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.NovaBridge Biosciences's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, NovaBridge Biosciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to December 2025.
NovaBridge Biosciences reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

40/ 100

Oct 5 40 → Nov 4 40

Valuation

Is the price right?

33/100

Weak

2/3 inputs reported · Partial data

Since last year: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-19.8%

SEC filings · 12 months to Dec 2025Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yieldUnavailable

Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0401 · MAD: 0.0401

Free cash flow yield-8.8%

SEC filings · 12 months to Dec 2025 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield98.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

11/100

Weak

2/3 inputs reported · Partial data

Since last year: No major change

Why

Weaker than most peers on:

▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-17.8%

SEC filings · 12 months to Dec 2025Reported value33% base weight · Z-score -3.62Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-366.7%

SEC filings · 12 months to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -16.87Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-20.0%

SEC filings · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last year: No major change

Why

Stronger than most peers on:

▲ Debt / equity
▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.50

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -2.60Sector median: 0.6250 · MAD: 0.3380

Current ratio8.09×

SEC filings · latest balance sheetReported value33% base weight · Z-score 3.97Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.02×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.98Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about NovaBridge Biosciences

Is NovaBridge Biosciences getting weaker?: Its latest SEC filing (Jun 16, 2026) showed no major changes. Its overall score is unchanged at 40/100 since Oct 28, 2026.
How is NovaBridge Biosciences valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -19.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -19.8% vs peers 1.5% (weaker than 100% of peers).
Is NovaBridge Biosciences growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is NovaBridge Biosciences?: Less profitable than most of its peers. Profitability scores 11/100 against 1,393 healthcare peers. Return on invested capital -366.7% vs a peer median of 4.7% (weaker than 100% of peers).Return on invested capital -366.7% vs peers 4.7% (weaker than 100% of peers).
How risky is NovaBridge Biosciences?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.02× vs a peer median of 0.22× (stronger than 84% of peers).Debt / equity 0.02× vs peers 0.22× (stronger than 84% of peers). Beta 1.50 vs a peer median of 0.63 (weaker than 88% of peers).Beta 1.50 vs peers 0.63 (weaker than 88% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Year ended Dec 31, 2023 · filed Jun 16, 2026 · compared with the year ended Dec 31, 2022

No major changes

Worth watching: NovaBridge Biosciences is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous year	Latest year	Change
Revenue (12 months)	−32.1M USD	632,000 USD	turned positive
Net income (12 months)	−363.5M USD	−46.3M USD	−87.3%
Free cash flow (12 months)	−166.5M USD	−20.6M USD	−87.6%
Cash	466.0M USD	210.6M USD	−54.8%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one year at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	47.3%	—	—	—	—	—
Operating margin	-2746.8%	3422.2%	-11395.1%	—	—	—
Net margin	-2648.7%	23923.5%	-32868.5%	—	—	—
Return on assets (ROA)	-41.6%	-62.8%	-56.3%	-10.5%	-17.8%	▼ 7.3 pts
Return on equity (ROE)	-51.2%	-88.8%	-85.6%	-11.1%	-20.0%	▼ 9.0 pts
Free cash flow margin	-1139.5%	10443.8%	-29107.9%	—	—	—
Current ratio	7.66×	4.78×	5.67×	20.90×	8.09×	▼ 61%
Quick ratio	7.62×	4.78×	—	—	—	—
Debt to equity	—	0.01×	0.02×	—	—	—
Interest coverage	—	-53078.00×	-706.05×	—	—	—

NBP price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.50 vs a peer median of 0.63)bigger price swings (beta 1.50 vs peers 0.63)

Not enough data: growth

Would rank #825 of 1,157 fully scored healthcare companies (bottom 29%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 39% from December 2022 to December 2025.

NovaBridge Biosciences had 39% more shares at December 2025 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.NovaBridge Biosciences had 39% more shares at December 2025 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.

NovaBridge Biosciences's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.NovaBridge Biosciences's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, NovaBridge Biosciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to December 2025.

NovaBridge Biosciences reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about NovaBridge Biosciences

Is NovaBridge Biosciences getting weaker?

Its latest SEC filing (Jun 16, 2026) showed no major changes. Its overall score is unchanged at 40/100 since Oct 28, 2026.

How is NovaBridge Biosciences valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -19.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -19.8% vs peers 1.5% (weaker than 100% of peers).

Is NovaBridge Biosciences growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is NovaBridge Biosciences?

Less profitable than most of its peers. Profitability scores 11/100 against 1,393 healthcare peers. Return on invested capital -366.7% vs a peer median of 4.7% (weaker than 100% of peers).Return on invested capital -366.7% vs peers 4.7% (weaker than 100% of peers).

How risky is NovaBridge Biosciences?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.02× vs a peer median of 0.22× (stronger than 84% of peers).Debt / equity 0.02× vs peers 0.22× (stronger than 84% of peers). Beta 1.50 vs a peer median of 0.63 (weaker than 88% of peers).Beta 1.50 vs peers 0.63 (weaker than 88% of peers). A relative measure, not a bankruptcy probability.

Previous year

Latest year

Change

Revenue (12 months)

−32.1M USD

632,000 USD

turned positive

Net income (12 months)

−363.5M USD

−46.3M USD

−87.3%

Free cash flow (12 months)

−166.5M USD

−20.6M USD

−87.6%

Cash

466.0M USD

210.6M USD

−54.8%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

47.3%

—

Operating margin

-2746.8%

3422.2%

-11395.1%

—

Net margin

-2648.7%

23923.5%

-32868.5%

—

Return on assets (ROA)

-41.6%

-62.8%

-56.3%

-10.5%

-17.8%

▼ 7.3 pts

Return on equity (ROE)

-51.2%

-88.8%

-85.6%

-11.1%

-20.0%

▼ 9.0 pts

Free cash flow margin

-1139.5%

10443.8%

-29107.9%

—

Current ratio

7.66×

4.78×

5.67×

20.90×

8.09×

▼ 61%

Quick ratio

7.62×

4.78×

—

Debt to equity

—

0.01×

0.02×

—

Interest coverage

—

-53078.00×

-706.05×

—